News

Ajanta Pharma Limited submitted a certificate to the BSE Limited and National Stock Exchange of India under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, as confirmed by MUFG Intime India Private Limited, formerly Link Intime India Private Limited, the company’s registrar and share transfer agent.

Aayush Agrawal, trustee of Aayush Agrawal Trust, disclosed the creation of a pledge on 4,60,000 equity shares of Ajanta Pharma Limited on September 28, 2026, for the purpose of issuing non-convertible debentures. The pledge represents 0.37% of the company`s total share capital, according to a filing with the BSE and National Stock Exchange of India.

Aayush Agrawal, trustee of Aayush Agrawal Trust, disclosed the release of a pledge on 98,185 equity shares of Ajanta Pharma Limited, citing loan repayment as the reason. The release, along with other releases by various entities including Yogesh M Agrawal, Rajesh M Agrawal, Ravi P Agrawal, and Aditya Birla Capital Ltd, occurred between September 21 and September 23, 2026.

Ajanta Pharma Limited will close its trading window for securities transactions from October 1, 2026, until 48 hours after the announcement of its financial results for the second quarter and half year ended September 30, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Ravi Agrawal, trustee of Ravi Agrawal Trust, released a pledge on 6,910 equity shares of Ajanta Pharma Limited on August 14, 2026, citing business financing as the reason, according to a regulatory filing with the BSE and National Stock Exchange. Aditya Birla Capital Limited was the lender, and Barclays Securities (India) Private Limited acted as the depositary participant.